Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine (OASIS (CM))

• ClinicalTrials.gov Identifier: NCT03832998
• Recruitment Status: Recruiting
• First Posted: February 6, 2019
• Last Update Posted: April 8, 2022
• Sponsor: Amgen
• Collaborator: Novartis
• Information provided by (Responsible Party): Amgen

Tracking Information

• First Submitted Date: January 29, 2019
• First Posted Date: February 6, 2019
• Last Update Posted Date: April 8, 2022
• Actual Study Start Date: September 5, 2019
• Estimated Primary Completion Date: August 14, 2024 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures (submitted: February 5, 2019)

Change from baseline in monthly migraine days (MMDs) [ Time Frame: Baseline through week 12 of the double blind treatment phase ]

To evaluate the effect of erenumab compared with placebo on the change in MMDs from baseline to week 9 through week 12 (month 3) of the double-blind treatment period (DBTP).

• Original Primary Outcome Measures: Same as current

Current Secondary Outcome Measures (submitted: February 6, 2019)

• Change in monthly headache days from baseline [ Time Frame: Baseline through week 12 of the double blind treatment phase ]
  To evaluate the effect of erenumab compared with placebo on the change from baseline in monthly headache days to week 9 through week 12 (month 3) of the double-blind treatment period (DBTP)
• Proportion of subjects with at least 50% reduction in monthly migraine days (MMDs) from baseline [ Time Frame: Baseline through week 12 of the double blind treatment phase ]
  To evaluate the effect of erenumab compared with placebo on the proportion of subjects with at least 50% reduction in MMDs from baseline to week 9 through week 12 (month 3) of the double-blind treatment period (DBTP)
• Change in monthly migraine days (MMDs) from baseline to the average of the first 3 months [ Time Frame: Baseline through week 12 of the double blind treatment phase ]
  To evaluate the effect of erenumab compared with placebo on the change in MMDs from baseline to the average of the first 3 months (week 1 through week 12) of the double-blind treatment period (DBTP).
• Change in monthly migraine days (MMDs) from baseline to the average of the first 6 months [ Time Frame: Completion of double blind treatment phase at 24 weeks ]
  To evaluate the effect of erenumab compared with placebo on the change in MMDs from baseline to the average of the 6 month (week 1 through week 24) double-blind treatment period (DBTP).
• Change in monthly average severity of migraine attacks from baseline (measured with a visual analogue scale) [ Time Frame: Baseline through week 12 of the double blind treatment phase ]
  To evaluate the effect of erenumab compared with placebo on the change from baseline in monthly average severity of migraine attacks to week 9 through week 12 (month 3) of the double-blind treatment period (DBTP). This will be measured in an electronic diary (eDiary) with a visual analogue scale.
• Change from baseline in migraine-related disability and productivity [ Time Frame: Baseline through week 12 of the double blind treatment phase ]
  To evaluate the effect of erenumab compared with placebo on the change from baseline in migraine-related disability and productivity as measured by the modified Pediatric Migraine Disability Assessment Questionnaire (modified PedMIDAS) to month 3 of the double-blind treatment period (DBTP).

Original Secondary Outcome Measures (submitted: February 5, 2019)

• Change in monthly headache days from baseline [ Time Frame: Baseline through week 12 of the double blind treatment phase ]
  To evaluate the effect of erenumab compared with placebo on the change from baseline in monthly headache days to week 9 through week 12 (month 3) of the double-blind treatment period (DBTP)
• Proportion of subjects with at least 50% reduction in monthly migraine days (MMDs) from baseline [ Time Frame: Baseline through week 12 of the double blind treatment phase ]
  To evaluate the effect of erenumab compared with placebo on the proportion of subjects with at least 50% reduction in MMDs from baseline to week 9 through week 12 (month 3) of the double-blind treatment period (DBTP)
• Change in monthly migraine days (MMDs) from baseline to the average of the first 3 months [ Time Frame: Baseline through week 12 of the double blind treatment phase ]
  To evaluate the effect of erenumab compared with placebo on the change in MMDs from baseline to the average of the first 3 months (week 1 through week 12) of the double-blind treatment period (DBTP).
• Change in monthly migraine days (MMDs) from baseline to the average of the first 6 months [ Time Frame: Completion of double blind treatment phase at 24 weeks ]
  To evaluate the effect of erenumab compared with placebo on the change in MMDs from baseline to the average of the 6 month (week 1 through week 24) double-blind treatment period (DBTP).
• Change in monthly average severity of migraine attacks from baseline (measured with a visual analogue scale) [ Time Frame: Baseline through week 12 of the double blind treatment phase ]
  To evaluate the effect of erenumab compared with placebo on the change from baseline in monthly average severity of migraine attacks to week 9 through week 12 (month 3) of the double-blind treatment period (DBTP). This will be measured in a daily eDiary with a visual analogue scale.
• Change from baseline in migraine-related disability and productivity [ Time Frame: Baseline through week 12 of the double blind treatment phase ]
  To evaluate the effect of erenumab compared with placebo on the change from baseline in migraine-related disability and productivity as measured by the modified PedMIDAS to month 3 of the double-blind treatment period (DBTP).

• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine
• Official Title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Erenumab in Children (6 to < 12 Years) and Adolescents (12 to < 18 Years) With Chronic Migraine (OASIS PEDIATRIC [CM])
• Brief Summary: This study will evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to <12 years) and adolescents (12 to <18 years) with chronic migraine. The study hypothesis is that in pediatric subjects with chronic migraine, the combined erenumab dose group has a greater reduction from baseline to week 9 through week 12 (month 3) in monthly migraine days (MMDs) when compared with placebo in the double-blind treatment phase (DBTP).

Detailed Description

This study is a Phase 3, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of Erenumab in migraine prevention in children (6 to <12 years) and adolescents (12 to <18 years) with chronic migraine.

The trial consists of four phases: screening (up to 3 weeks of initial screening and a 4-week prospective baseline phase); the double-blind treatment phase (24 weeks) in which participants receive placebo or Erenumab dose 1, dose 2 or dose 3 (based on participant's body weight) via subcutaneous injection once a month; the optional dose level blinded extension phase (40 weeks), in which all participants are assigned to receive dose 1, dose 2 or dose 3 of Erenumab; and a 12 weeks safety follow-up phase (16 weeks after the last dose of investigational drug).

The study intends to enroll 286 participants (256 adolescents and 30 children).

• Study Type: Interventional
• Study Phase: Phase 3
• Study Design: Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor); Primary Purpose: Treatment
• Condition: Migraine

Intervention

• Drug: Erenumab Dose 1
  Subjects in the low body-weight group at day 1 and who are randomized to Dose Level 1 will receive this dose.
  Other Names:

  • AMG 334
  • Aimovig®
• Drug: Erenumab Dose 2
  Subjects in the low body-weight group at day 1 who are randomized to Dose Level 2 and subjects in the high body-weight group at day 1 who are randomized to Dose Level 1 will receive this dose.
  Other Names:

  • AMG 334
  • Aimovig®
• Drug: Erenumab Dose 3
  Subjects in the high body-weight group at day 1 who are randomized to Dose Level 2 will receive this dose.
  Other Names:

  • AMG 334
  • Aimovig®
• Other: Placebo
  Placebo matching dose for erenumab dose 1, 2 and 3.

Study Arms

• Experimental: Dose Level 1
  Subjects will be randomized to one of two doses determined by their body weight at Day 1.
  Interventions:

  • Drug: Erenumab Dose 1
  • Drug: Erenumab Dose 2
• Experimental: Dose Level 2
  Subjects will be randomized to one of two doses determined by their body weight at Day 1.
  Interventions:

  • Drug: Erenumab Dose 2
  • Drug: Erenumab Dose 3
• Placebo Comparator: Placebo
  Intervention: Other: Placebo

• Publications *: Not Provided

Recruitment Information

• Recruitment Status: Recruiting
• Estimated Enrollment (submitted: February 5, 2019): 286
• Original Estimated Enrollment: Same as current
• Estimated Study Completion Date: December 27, 2026
• Estimated Primary Completion Date: August 14, 2024 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• Children (6 to less than 12 years of age) or adolescent (12 to less than 18 years of age) at the time of signing, if developmentally appropriate, the formal assent to participate to the study.
• Subject's parent or legal representative has provided written informed consent before initiation of any study-specific activities/procedures.
• History of migraine (with or without aura) for ≥ 12 months before screening according to the IHS Classification ICHD-3 (Headache Classification Committee of the International Headache Society, 2013) ICHD-3 specifications for pediatric migraine (subjects aged less than 18 years), should be considered for the diagnosis of migraine.
• History of ≥ 15 headache days per month of which ≥ 8 headache days were assessed by the subject as migraine days per month in each of the 3 months prior to screening.
• Migraine frequency: greater than or equal to 8 migraine days based on the eDiary data during the last 28 days of the baseline phase if more than 28 days in duration.
• Headache frequency of greater than or equal to 15 headache days based on the eDiary data during the last 28 days of the baseline phase if more than 28 days in duration.
• Demonstrated at least 80% compliance with the eDiary based on the last 28 days of the baseline period, if more than 28 days in duration (eg, completing eDiary items for at least 23 out of the last 28 days of the baseline phase).

Key Exclusion Criteria:

• History of cluster headache or hemiplegic migraine headache.
• Chronic migraine with continuous pain, in which the subject does not have any pain free periods (of any duration) during the 1 month prior to screening.
• No therapeutic response with greater than 3 medication categories for prophylactic treatment of migraine after an adequate therapeutic trial. No therapeutic response is defined as no reduction in headache frequency, duration, or severity after administration of the medication for at least 6 weeks at the generally-accepted therapeutic dose(s) based on the investigator's assessment.
• History of suicidal behavior or the subject is at risk of self-harm or harm to others.
• History of major psychiatric disorder. Subjects with anxiety disorder and/or mild major depressive disorder (Patient Health Questionnaire Modified for Adolescents [PHQ-A] score 9) are permitted in the study if they are considered by the investigator to be stable and are taking no more than 1 medication for each disorder. Subjects must have been on a stable dose within the 3 months before the start of the baseline phase.

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 6 Years to 17 Years (Child)
• Accepts Healthy Volunteers: No

Contacts

Contact: Amgen Call Center; 866-572-6436; medinfo@amgen.com

• Listed Location Countries: Belgium, Canada, Colombia, Finland, Germany, Hungary, Italy, Japan, Poland, Russian Federation, United Kingdom, United States

Administrative Information

• NCT Number: NCT03832998
• Other Study ID Numbers: 20160354; 2017-002399-23 ( EudraCT Number )
• Has Data Monitoring Committee: Yes

U.S. FDA-regulated Product

• Studies a U.S. FDA-regulated Drug Product: Yes
• Studies a U.S. FDA-regulated Device Product: No

IPD Sharing Statement

• Plan to Share IPD: Yes
• Plan Description: De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.
• Supporting Materials: Study Protocol
• Supporting Materials: Statistical Analysis Plan (SAP)
• Supporting Materials: Informed Consent Form (ICF)
• Supporting Materials: Clinical Study Report (CSR)
• Time Frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
• Access Criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
• URL: https://www.amgen.com/datasharing

• Responsible Party: Amgen
• Study Sponsor: Amgen
• Collaborators: Novartis

Investigators

• Study Director: MD; Amgen

• PRS Account: Amgen
• Verification Date: April 2022